1961•PubMedRequires access
The diphasic effect of N-methyl-3-piperidyl-(N',N')-diphenylcarbamate HCI (MPDC) on the metabolism of hexobarbital.
David M. Serrone, James M. Fujimoto
Open publisher page 22 citations
Abstract
By pretreating mice with N-methyl-3-piperidyl - (N9,N9) - diphenylcarbamate HCl (MPDC) a diphasic effect (A and B) on hexobarbital sleeping time is produced. Phase A is associated with an increase in hexobarbital sleeping times. This phase is attributed to inhibition of the metabolism of hexobarbital based on previous findings. Phase B is associated with a decrease in hexobarbital sleeping times. This decrease is associated with an increase in the metabolism of hexobarbital. Observations in mice of lower total body concentrations of hexobarbital in vivo and increased disappearance of hexobarbital from the liver homogenates in vitro support the conclusion. An adaptive increase in the enzyme system which metabolizes hexobarbital is postulated. This mechanism is suggested by the experiments with dl -ethionine in vivo .